Akademik Veri Yönetim Sistemi
Tez Türü: Tıpta Uzmanlık
Tezin Yürütüldüğü Kurum: Sağlık Bilimleri Üniversitesi, İstanbul Yedikule Göğüs Hastalıkları Ve Göğüs Cerrahisi Sağlık Uygulama Ve Araştırma Merkezi, Dahili Tıp Bilimleri Bölümü, Türkiye
Tez Danışmanı: Dr. Öğr. Üyesi Murat Kıyık
Tezin Onay Tarihi: 2019
Tezin Dili: Türkçe
Özet:
Introduction/Objective: To determine the prognostic significance of programmed death-ligand 1(PD-L1) in stage 4 non-small cell lung cancer (NSCLC). Materials and Method: From January 2016 to January 2018, the hospital records were examined and all of the patients included in the study were diagnosed with non-small cell lung cancer in our hospital. The patient records were reviewed retrospectively. All patients had stage 4 NSCLC and PD-L1 results were recorded. Cases with EGFR, ALK and ROS mutation positive and immunotherapy were not included in the study. Results: Data of 38 patients were included in the study. 33 (86.8%) of the cases participated in the study were male and 5 (13.2%) were female. The median mean age was 63 years. 28 (73.7%) of the cell types of the cases were adenocarcinoma, 6 (15.8%) were non specified non-small cell lung cancer type and 4 (10.5%) were squamous cell lung cancer. In our study, PD-L1 ≥ 50% were defined as positive group (PG) and values <50% were named as negative group (NG). These two groups were compared for prognosis. There were 27 cases in the negative group (NG) and 11 in the positive group (PG). It was found that 21 (67.8%) of 27 NG cases and 3 (21.3%) of 11 PG cases died. In 38 cases, a total of 24 patients (73.2%) died. Mean survival was 10.81 months in NG, while median survival was 28.54 months in PG. One-year survival was found to be 30% in NG and 79% in PG and (Log-Rank test with p = 0.046) PG was significantly better than survival. Conclusion: When we examined the results of our study, PD-L1 ≥ 50% patients were found to live significantly longer than those with PD-L1 values below 50%. These values suggest that PD-L1 will gain more importance in the future for the prognosis of non-small cell lung cancer.